Reply: Management of tricuspid regurgitation by caval valve implantation: From technical feasibility to evaluation of efficacy

Journal of the American College of Cardiology

Volumn 62, Issue 23, 2013, Pages 2259-

  Laule, Michael ^a   Stangl, Verena ^b   Baumann, Gert ^b   Stangl, Karl ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFICIAL HEART PACEMAKER; CAVA VEIN; CAVAL VALVE IMPLANTATION; HEART CATHETERIZATION; HEART FAILURE; HEART RIGHT VENTRICLE FUNCTION; HEART VALVE REPLACEMENT; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INFERIOR CAVA VEIN; LETTER; PERCUTANEOUS AORTIC VALVE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SECONDARY TRICUSPID REGURGITATION; SURGICAL TECHNIQUE; TREATMENT OUTCOME; TRICUSPID VALVE REGURGITATION; VEIN DIAMETER;

EID: 84889821695     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.07.092     Document Type: Letter

References (1)

1. M. Laule, V. Stangl, W. Sanad, A. Lembcke, G. Baumann, and K. Stangl Percutaneous transfemoral management of severe secondary tricuspid regurgitation with Edwards Sapien XT bioprosthesis: first-in-man experience J Am Coll Cardiol 61 2013 1929 1931